Betahistin MCC 24mg

Betahistine is indicated for the treatment of Meniere Syndrome, its symptoms including vertigo (often associated with nausea and/or vomiting), tinnitus, loss of hearing.
Pharmaco-therapeutic group: anti vertigo products, ATC code N07CA01.
Daily usual dose is of 24-48mg betahistine diclorhydrate, administered in several doses.
Children and teenagers:
BETAHISTIN MCC is not recommended for use in children under 18 years old due to the lack of data regarding safety and efficacy.
BETAHISTIN MCC is contraindicated in cases of:
• hypersensitivity to the active ingredient or any other of the excipients.
• pheochromocytoma
• pregnancy and lactation